Nivolumab, as a PD-1 inhibitor, should be investigated for its irAEs, such as: 1) Before and during the administration of drugs, perform cardiac related examinations, which include cardiac biomarkers and ECG 2) While monitoring and observation some irAEs prodrome symptoms, including dyspnea, myalgia, fatigue, blepharoptosis, and myasthenia; 3) The induction period of irAEs is different so management of the entire process is essential, and any abnormality findings should be addressed quickly. The gene discussed is PDCD1; the disease is Fatigable weakness.